We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Changes in Eye Pressure and Anterior Chamber Depth With Oral Endothelin Antagonist Therapy

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00452283
First Posted: March 27, 2007
Last Update Posted: January 31, 2013
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
University of Colorado, Denver
March 23, 2007
March 27, 2007
January 31, 2013
March 2007
May 2011   (Final data collection date for primary outcome measure)
Occurence of nerve fiber layer abnormalities [ Time Frame: Single Exam ]
Not Provided
Complete list of historical versions of study NCT00452283 on ClinicalTrials.gov Archive Site
Optic Nerve Head Structure [ Time Frame: Single Exam ]
Not Provided
  • Visual Field Defects [ Time Frame: Single Exam ]
  • Retinal Blood Flow Changes [ Time Frame: Single Exam ]
Not Provided
 
Changes in Eye Pressure and Anterior Chamber Depth With Oral Endothelin Antagonist Therapy
The Effect of a Systemic Non-selective Endothelin Antagonist on Intraocular Pressure and Anterior Depth in Pulmonary Hypertension Patients.

There is growing evidence that a cause of glaucoma is linked to circulatory problems and poor auto-regulation of blood flow to the optic nerve. Pulmonary hypertension (PH)is a disease characterized by low oxygen levels in the blood and altered blood circulation. The decrease in oxygen delivery to the optic nerve could lead to the loss of nerve fiber layer(NFL)in the retina and the resulting visual field compromise. This situation is characteristic of glaucoma. The ability to identify NFL thinning early could lead to earlier diagnosis of glaucoma and more effective treatment to limit dysfunction from visual field loss.

We hypothesize that the rate of structural damage to the NFL, a feature of glaucoma, is higher in patients with PH than expected in healthy populations lacking this disease.

Not Provided
Observational
Observational Model: Case-Only
Time Perspective: Prospective
Not Provided
Not Provided
Non-Probability Sample
Patients diagnosed with pulmonary hypertension
  • Glaucoma
  • Pulmonary Hypertension
Not Provided
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
23
May 2011
May 2011   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • diagnosed with pulmonary hypertension
  • between the ages of 18 and 80 years
  • ability to undergo the various ocular exams.

Exclusion Criteria:

  • patients with other diseases that could affect the nerve fiber layer
  • special populations; ie children, pregnancy, lactating females, prisoners
Sexes Eligible for Study: All
18 Years to 80 Years   (Adult, Senior)
No
Contact information is only displayed when the study is recruiting subjects
United States
 
 
NCT00452283
06-0792
No
Not Provided
Not Provided
University of Colorado, Denver
University of Colorado, Denver
Not Provided
Principal Investigator: Malik Y. Kahook, M.D. University of Colorado School of Medicine
University of Colorado, Denver
January 2013